Semax
Neuropeptide (nootropic)
Status & caution. Russian-developed; not FDA-approved. Among the 12 peptides removed from Category 2 in April 2026 and scheduled for PCAC review on 24 July 2026. Evidence base is largely Russian; Western trials are limited.
At a glance
Indications & what it's studied for
Reported nootropic and neuroprotective effects (focus, cognition, stroke recovery in its country of origin); modulates BDNF and dopaminergic/serotonergic systems.
Contraindications & cautions
No established Western contraindications; pregnancy data lacking.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Typically intranasal in small daily doses; unvalidated outside its origin.
Routes of administration
Intranasal spray; subcutaneous in some community use.
Don't combine with
Caution with other CNS stimulants/nootropics.
Reported to stack with
Commonly paired with Selank.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Russian clinical use including in stroke; limited independent Western evidence.
Before acting on anything here, see Safety & the grey market and how to read a COA.